Loading...
01/11 03:38
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Despite some positive aspects such as increased EBITDA margin outlook and share repurchase program, the overall sentiment is negative. The company faces organic sales decline, economic and competitive pressures, and operational risks. The financial performance shows a revenue decline and flat gross margin. The Q&A reveals concerns about tariffs and unresolved tax issues. The unchanged EPS guidance and expected sales decline further contribute to a negative sentiment.
Revenue $879 million, down 7.7% year-over-year, primarily due to a negative 4% impact from Byte and foreign currency negatively impacting sales by approximately 330 basis points.
Organic Sales Declined 4.4% year-over-year, with double-digit growth in equipment and instruments, offset by declines in CAD/CAM and IPS.
Adjusted Gross Margin Roughly flat year-over-year, reflecting operational efficiency.
Adjusted EBITDA Margin Expanded 220 basis points year-over-year, benefiting from lower operating expenses and transformational savings.
Adjusted EPS $0.43, up 3.7% year-over-year, largely due to higher adjusted EBITDA margins and a lower share count, partially offset by a higher tax rate.
Operating Cash Flow $7 million, down from $25 million in the prior year quarter, primarily due to timing of cash collections and a higher build of inventory.
Cash and Cash Equivalents $398 million as of March 31.
Net Debt-to-EBITDA Ratio 3x, consistent with the prior quarter.
New Product Introductions: Wellspect Healthcare delivered another quarter of growth across all geographies, fueled by new product introductions and solid execution.
DS Core Ecosystem: The DS Core ecosystem continues to gain traction with over 42,000 unique users and 50,000 connected devices, processing over 100,000 lab orders each month.
Primescan 2 Enhancements: Enhanced Primescan 2 with new functionality, including a 50% reduction in Internet speed requirements and 90% faster SureSmile simulations.
DS Core Diagnosed: Added DS Core diagnosed, integrating an AI-powered 3D rendering tool for better patient communication, currently available in Europe and pending 510(k) clearance in the U.S.
Market Growth: Organic sales increased 1.1% in Europe, driven by performance in Germany, equipment and instruments, SureSmile, and Wellspect.
U.S. Market Decline: U.S. organic sales declined 14.9%, primarily due to the negative 9.8% impact from Byte.
Rest of World Growth: Rest of World organic sales grew 3.1%, with growth in imaging, Wellspect, and implants in China.
Operational Efficiency: Adjusted EBITDA margins expanded 220 basis points, benefiting from lower operating expenses and reflecting transformational savings.
Supply Chain Optimization: Completed the closure of one manufacturing site, bringing the total number of closed sites to 10, optimizing the global supply chain.
ERP Modernization: Continued progress on ERP modernization with two additional phases rolled out in the U.S.
Strategic Actions for 2025: Embarked on strategic actions focused on customer and return-centric innovation, clinical education, and commercial excellence.
Virtual Sales Team: The virtual sales team now makes over 2,000 customer calls a day, generating several million dollars in leads.
Customer Engagement Initiatives: Launched revamped company and SureSmile websites to improve customer interactions and designed a new e-commerce platform.
Global Trade Situation: Current and potential tariffs create headwinds and risks for the business, necessitating plans to mitigate impacts.
Economic Conditions: Concerns about rapidly changing economic conditions affecting patient footfall and treatment acceptance rates.
Supply Chain Optimization: Ongoing supply chain transformation and closure of manufacturing sites may pose operational risks.
Regulatory Issues: Pending regulatory clearances for new products may impact market entry and sales.
Competitive Pressures: Declines in certain product segments due to competitive pressures and changing market dynamics.
Customer Sentiment: Drop in U.S. census sentiment indicating potential impacts on patient volume and procedure utilization.
Innovation Pipeline: The projected value of the NPD portfolio has more than doubled over the last 12 months, with a focus on cloud-based software and solutions.
Customer Engagement: Launched revamped company and SureSmile websites to improve customer interactions and designed a new e-commerce platform.
Virtual Sales Team: The virtual sales team is making over 2,000 customer calls a day, generating significant revenue and leads.
ERP Modernization: Continues with more deployments planned, including remaining U.S. deployments and additional European launches.
Supply Chain Transformation: Ongoing efforts to optimize the supply chain and SKU management.
2025 Organic Sales Outlook: Maintaining outlook for organic sales to decline 2% to 4%, with a 2% Byte impact for the full year.
2025 Adjusted EPS Outlook: Adjusted EPS remains unchanged in the range of $1.80 to $2.00.
2025 Reported Sales Outlook: Revised to $3.6 billion to $3.7 billion, up from $3.5 billion to $3.6 billion.
Adjusted EBITDA Margin: Increased outlook to greater than 19% due to positive FX impacts.
Q2 2025 Expectations: Expecting mid-single-digit decline in organic sales, with adjusted EPS anticipated to increase year-over-year.
Share Repurchase Program: In Q1, the company reported a lower share count, contributing to an adjusted EPS of $0.43, which is up 3.7% from the prior year.
The earnings call summary presents a mixed outlook. While there are positive aspects like innovation investments and strategic plans, there are concerns over declining U.S. sales and unclear timelines for growth. The Q&A section reveals uncertainty in management's responses and lack of clarity on financial impacts, balancing the positive elements. These factors suggest a neutral sentiment, with no strong catalysts for significant stock price movement.
The earnings call summary shows mixed results: strong product development initiatives and strategic planning, but challenges in certain segments and geographic areas. The Q&A reveals management's cautious stance on macroeconomic factors and tariff impacts, along with a lack of specific details on addressing current issues. Despite some positive future guidance, the overall sentiment remains neutral due to uncertainties and the unchanged EPS outlook.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
